CR 18-070 - Relating to scheduling para-chloroisobutyryl fentanyl.
CR 18-069 - Relating to scheduling of MT-45.
CR 18-055 - Relating to scheduling of oral solutions containing dronabinol.
CR 18-024 - Relating to excluding from scheduling naldemine.
CR 18-023 - Relating to scheduling of ortho-fluorofentanyl.
CR 18-022 - Relating to scheduling of FUB-AMB.
CR 17-089 - Relating to scheduling 4-Fluoroisobutyryl fentanyl
CR 17-088 - Relating to scheduling 5F-ADB, 5F-AMB, ADB-FUBINACA, MDMB-CHMICA, and MDMB-FUBINACA
CR 17-087 - Relating to scheduling 4-MePPP and a-PBP
CR 17-086 - Relating to scheduling MAB-CHMINACA
CR 17-085 - Relating to scheduling of AB-CHMINACA, AB-PINACA, and THJ-2201
CR 17-075 - Relating to scheduling cyclopropyl fentanyl.
CR 17-040 - Relating to scheduling acryl fentanyl.
CR 17-028 - Relating to the operation of the prescription drug monitoring program.
CR 17-023 - Relating to scheduling of AH-7921.
CR 17-022 - Relating to scheduling of eluxadoline.
CR 17-021 - Relating to scheduling of acetyl fentanyl.
CR 17-020 - Relating to scheduling of U-47700.
CR 17-009 - Relating to scheduling of brivaracetam.
CR 17-008 - Relating to scheduling of AB-FUBINACA and ADB-PINACA.
CR 17-007 - Relating to scheduling of thiafentanil.
CR 16-081 - Relating to scheduling of beta-hydroxy thiofentanyl and butyrk fentanyl.
CR 16-060 - Relating to exclusion of [123I] ioflupane.
CR 16-059 - Relating to scheduling furanyl fentanyl.
CR 15-101 - Relating to the operation of the prescription drug monitoring program.
CR 15-083 - Relating to measurement of controlled substances for purposes of special use authorizations.
CR 15-070 - Relating to submission of data to the prescription drug monitoring program.
CR 15-068 - Relating to exclusion of naloxegol.
CR 15-009 - Relating to scheduling Suvorexant as a schedule IV controlled substance.
CR 15-008 - Relating to scheduling tramadol as a schedule IV controlled substance.
CR 15-007 - Relating to rescheduling hydrocodone combination products.
